Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients - Phase I/II Study.

NCT01898039 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT01898039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01898039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients - Phase I/II Study.
Lead sponsor
Hadassah Medical Organization
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 31, 2013
Completion date
April 30, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma